Balchem

Balchem Corp. provides marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products and Industrial Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment comprises nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The Industrial Products segment refers to certain derivatives of choline chloride which manufactured and sold into industrial applications as a component for hydraulic fracturing of shale natural gas wells. The company was founded in January 1967 and is headquartered in Montvale, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Balchem reports record 2022 earnings, eyes growth amid challenges

Balchem's strong performance in 2022, driven by record sales and earnings, positions them well for future growth. Strategic acquisitions and market studies provide opportunities for expansion despite temporary challenges.

Balchem reports record Q1 revenues, navigates market challenges strategically

Balchem's Q1 2023 performance reflects solid financial results, operational efficiency, and progress in sustainability initiatives.
Despite market challenges, the company showcased resilience, innovation, and a strategic focus on long-term growth.
Opportunities for growth and differentiation exist through market expansion, product innovation, and continued sustainability efforts.
Balchem's strong financial foundation, coupled with a commitment to sustainability, underpins its strategic positioning for future success.

Balchem reports stable Q2 earnings, eyes growth in nutrition sector

Balchem delivered a mixed performance in Q2 2023 with revenue decline but improved profitability metrics.
The company faces challenges in revenue growth and leadership transition but maintains financial stability.
Opportunities lie in exploring new markets, leveraging cash reserves, and capitalizing on manufacturing investments.

Balchem (BCPC) reports solid Q3 results amid market challenges

Balchem's Q3 performance reflects resilience amidst challenges, with a focus on innovation, quality, and operational efficiency.
While facing market uncertainties and higher interest expenses, the company's strategic strengths in key segments position it for growth.
Opportunities lie in leveraging partnerships, consumer awareness efforts, and strategic initiatives to drive future sales and profitability.

Balchem reports record earnings in Q4 2023, eyes growth opportunities

Balchem's Q4 2023 performance showcased resilience with record earnings and strong profitability despite challenges in certain segments. Strategic initiatives and focus on sustainability and growth areas like Human Nutrition & Health position the company well for future success. Optimism for 2024 and potential partnerships signal a promising outlook for Balchem.

Balchem reports robust Q1 earnings, focuses on growth strategies

Balchem's Q1 2024 performance reflects strong financial results, driven by record sales and adjusted EBITDA, despite challenges in specific segments.
The company's focus on sustainability, marketing initiatives, and margin improvement positions it well for future growth and market expansion.
Addressing challenges in the Animal Nutrition & Health segment while leveraging opportunities in key segments like Human Nutrition & Health is crucial for sustained success.
Balchem's strategic partnerships, marketing efforts, and participation in investor conferences signal a proactive approach to driving growth and enhancing shareholder value.

Balchem reports solid Q2 earnings, eyes growth amid segment challenges

Balchem's Q2 2024 performance reflects resilience and growth, particularly in the Human Nutrition & Health and Specialty Products segments, despite challenges in the Animal Nutrition & Health segment.
The company's focus on innovation, debt reduction, and operational efficiency positions it well for future opportunities and sustained financial strength.
With a solid financial foundation, Balchem is poised to navigate challenges, capitalize on growth opportunities, and drive value for shareholders in the coming quarters.

Balchem (BCPC) reports record earnings, eyes growth amid margin challenges

Balchem (BCPC) delivered strong financial results in Q3 2024, driven by solid performance across its segments and successful new product launches. While anticipating margin moderation, the company remains optimistic about continued growth opportunities, especially in key segments. Balchem's focus on strategic investments and market stability positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Balchem Corp. provides marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health and Specialty Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment consists of nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The company was founded in January 1967 and is headquartered in Montvale, NJ.

Balchem Corp (BCPC) CEO Ted Harris on Q1 2019 Results - Earnings Call Transcript

Balchem Corporation announced Thursday that it signed a definitive agreement to acquire Chemogas NV, a privately held specialty gases company based in Grimbergen, Belgium.

Balchem Buys Belgian Specialty Gases Manufacturer Chemogas

Blachem (BCPC) delivered earnings and revenue surprises of 5.80% and -4.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Blachem (BCPC) Surpasses Q1 Earnings Estimates

Apple

Celgene

Gilead Sciences

Alphabet

Find out which stocks have performed the best over the past 20 years, which industries generated the most growth, and how much these stocks appreciated.

The 6 Best-Performing Stocks in the Past 20 Years

News for Balchem Stock (BCPC)